COVID-19
Get involved in the development of treatments and vaccines.
Take care of your non-COVID-19-related health.
Genomic Sequencing Aims to Help Define Changes in Transmission and Identify New Mutations
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 7, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been awarded a contract from the Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of samples of SARS-CoV-2, the virus that causes COVID-19.
Labcorp has been regularly tracking mutations of the coronavirus throughout the pandemic, including a new variant strain of SARS-CoV-2 (VOC 202012/01 or B.1.1.7) in the UK and more recently in the US, to determine the impact it would have on our PCR test sensitivity. To date, we have not seen any impact. The B.1.1.7 strain is detectable by our current molecular testing.
Kit Can Allow More People to Get Tested, Helping Reduce the Spread of the Virus and Improving the Health of Communities
Pixel by LabCorp™ COVID-19 Test Home Collection Kit is first to receive FDA authorization for over-the-counter purchase
INDIANAPOLIS, Dec.
Quantitative Test is Used to Assess Immune Response and to Support Other Scientific Research
Eases the Ability to Safely Travel, Enter Workplaces, and Attend Public Events
Molecular
tests performed
Molecular test
capacity per day**
Antibody
tests performed
Antibody test
capacity per day**
Update as of January 8, 2021. Molecular test capacity updated January 11, 2021.
*A $10 non-refundable physician fee is charged for the IgG antibody test if it is requested through Labcorp.com
**Capacity numbers are subject to sufficient equipment and supplies
Updated January 8, 2021
